Martin L Bryant, 6451 Littleton St, Springfield, MA 01104

6602664, Aug 5, 2003

Feb 26, 2001

09/793346

Raymond F. Schinazi - Decatur GA
Martin L. Bryant - Carlisle MA
Maureen W. Myers - Carlisle MA

Emory University - Atlanta GA
Idenix Pharmaceuticals, Inc. - Cambridge MA

C12Q 168

435 6, 536 282, 514 51

It has been discovered that 3â-azido-2â,3â-dideoxyuridine (CS-87) induces a transient mutation in HIV-1 at the 70 codon (K to R, i. e. , lysine to arginine) of the reverse transcriptase region of the virus. Based on this discovery, a method and composition for treating HIV is provided that includes administering CS-87 or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70 codon of the reverse transcriptase region. This invention can be practiced by referring to the published mutation patterns for known anti-HIV drugs, or by determining the mutation pattern for a new drug.

6194391, Feb 27, 2001

Jun 24, 1999

9/339133

Raymond F. Schinazi - Decatur GA
Martin L. Bryant - Carlisle MA
Maureen W. Myers - Carlisle MA

Emory University - Atlant GA
Norvirio Pharmaceuticals Limited - Grand Cayman

A61K 3170
C12Q 168

514 50

It has been discovered that 3'-azido-2',3'-dideoxyuridine (CS-87) induces a transient mutation in HIV-1 at the 70. sup. th codon (K to R, i. e. , lysine to arginine) of the reverse transcriptase region of the virus. Based on this discovery, a method and composition for treating HIV is provided that includes administering CS-87 or its pharmaceutically acceptable salt or prodrug to a human in need of therapy in combination or alternation with a drug that induces a mutation in HIV-1 at a location other than the 70. sup. th codon of the reverse transcriptase region. This invention can be practiced by referring to the published mutation patterns for known anti-HIV drugs, or by determining the mutation pattern for a new drug.